Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Atosiban

1

II.a Pulmonary edema, noncardiogenic (NCPE)

1
Last update : 20/01/2012
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist

Publications

Atosiban-induced acute pulmonary edema: A rare but severe complication of tocolysis.
Heliyon 2023 May;9;e15829 2023 May
A case of severe non-cardiogenic pulmonary edema in a woman treated with atosiban for preterm labor.
European review for medical and pharmacological sciences 2023 Feb;27;1305-1310 2023 Feb
The combination of corticosteroid and tocolytic therapy in a preeclamptic patient is a risk factor for the development of acute pulmonary oedema.
International journal of obstetric anesthesia 2018 May;34;113-114 2018 May
Non-cardiogenic pulmonary edema in a woman treated with atosiban for preterm labor.
European journal of obstetrics, gynecology, and reproductive biology 2017 Dec;219;132-133 2017 Dec
Severe non-cardiogenic pulmonary oedema secondary to atosiban and steroids.
International journal of obstetric anesthesia 2011 Apr;20;189-90 2011 Apr
Non-cardiogenic lung edema in a woman treated with atosiban for preterm labor.
Journal of perinatal medicine 2008;36;455-7 2008

Powered by

  • ^
  • Contact
  • Cookies
  • About

The Pneumotox website uses cookies. By accessing or using our website, you consent to the collection, use and disclosure of the garnered information in accordance with our privacy policy.

Learn more about cookies